KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 125 filers reported holding KEROS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $404,876 | -85.8% | 12,700 | -82.1% | 0.04% | -88.3% |
| Q2 2023 | $2,844,744 | -45.5% | 70,800 | -42.1% | 0.32% | -41.6% |
| Q1 2023 | $5,222,893 | -53.3% | 122,316 | -47.5% | 0.54% | -66.3% |
| Q4 2022 | $11,194,230 | +103.8% | 233,116 | +59.7% | 1.61% | +115.3% |
| Q3 2022 | $5,493,000 | – | 146,000 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |